https://foreseen.bio/ 2026-06-18T12:54:30.000Z weekly 1 https://foreseen.bio/news 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/contact 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/search 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/privacy 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/terms 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-cn 2026-06-18T12:54:30.000Z weekly 1 https://foreseen.bio/zh-cn/news 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-cn/contact 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-cn/search 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-cn/privacy 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-cn/terms 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-hk 2026-06-18T12:54:30.000Z weekly 1 https://foreseen.bio/zh-hk/news 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-hk/contact 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-hk/search 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-hk/privacy 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/zh-hk/terms 2026-06-18T12:54:30.000Z monthly 0.7 https://foreseen.bio/news/aacr-2026-ipn60300-phase-1-2-fih-study 2026-05-14T16:44:04.159Z monthly 0.6 https://foreseen.bio/news/aacr-2026-ipn60300-preclinical-characterization 2026-05-14T16:44:04.159Z monthly 0.6 https://foreseen.bio/news/aacr-2026-itga2-adc-target 2026-05-14T16:44:04.159Z monthly 0.6 https://foreseen.bio/news/aacr-2026-tps-first-in-class-therapeutic-target 2026-05-14T16:44:04.159Z monthly 0.6 https://foreseen.bio/news/ipsen-foreseen-fs001-global-license 2026-05-01T00:00:00.000Z monthly 0.8 https://foreseen.bio/news/upstream-engine-for-novel-target-discovery 2026-05-01T00:00:00.000Z monthly 0.6 https://foreseen.bio/news/clinical-proteomics-to-translatable-targets 2026-05-01T00:00:00.000Z monthly 0.6 https://foreseen.bio/zh-cn/news/aacr-2026-ipn60300-phase-1-2-fih-study 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-cn/news/aacr-2026-ipn60300-preclinical-characterization 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-cn/news/aacr-2026-itga2-adc-target 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-cn/news/aacr-2026-tps-first-in-class-therapeutic-target 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-cn/news/ipsen-foreseen-fs001-global-license 2026-05-01T00:00:00.000Z monthly 0.8 https://foreseen.bio/zh-cn/news/clinical-proteomics-to-translatable-targets 2026-05-01T00:00:00.000Z monthly 0.6 https://foreseen.bio/zh-cn/news/upstream-engine-for-novel-target-discovery 2026-05-01T00:00:00.000Z monthly 0.6 https://foreseen.bio/zh-hk/news/aacr-2026-ipn60300-phase-1-2-fih-study 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-hk/news/aacr-2026-ipn60300-preclinical-characterization 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-hk/news/aacr-2026-itga2-adc-target 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-hk/news/aacr-2026-tps-first-in-class-therapeutic-target 2026-05-14T17:35:33.852Z monthly 0.6 https://foreseen.bio/zh-hk/news/ipsen-foreseen-fs001-global-license 2026-05-01T00:00:00.000Z monthly 0.8 https://foreseen.bio/zh-hk/news/clinical-proteomics-to-translatable-targets 2026-05-01T00:00:00.000Z monthly 0.6 https://foreseen.bio/zh-hk/news/upstream-engine-for-novel-target-discovery 2026-05-01T00:00:00.000Z monthly 0.6